Thompson Street Capital Partners, alongside LifeSpan Biosciences, has acquired Absolute Antibody, enhancing its offering in recombinant antibody technology for research and diagnostics.

Target Company Information

Absolute Antibody, Ltd., based in Redcar, UK, is a prominent manufacturer and developer of recombinant antibodies primarily serving the research and diagnostic markets. Founded in 2012, the company was established with the mission of making engineered recombinant antibodies accessible to various sectors. Absolute Antibody specializes in recombinant antibody technology, offering services such as antibody sequencing, engineering, and recombinant production, alongside an extensive catalog of recombinant antibodies and Fc Fusion proteins designed in innovative formats.

In collaboration with its sister company, Kerafast Inc., located in Boston, Absolute Antibody plays a crucial role in facilitating access to unique lab-made reagents. The company's well-established reputation means that it is relied upon by some of the largest academic research institutions and diagnostic providers for recombinant antibodies and antibody engineering services, particularly for their critical and time-sensitive projects. As part of its expansion strategy, Absolute Antibody aims to further grow its leading catalog of recombinant antibodies by enhancing internal research and development capabilities and expanding service offerings in collaboration with its customers.

Industry Overview

The life sciences industry in the UK represents a significant market for research and diagnostic tools, with a continuous demand for innovative solutions. The country is home to numerous prestigious academic institutions and research centers, making it a hub for scientif